

Angiotensin Receptor Blocker is Associated with A Lower Fracture Risk: An Updated Systematic Review and Meta-Analysis

Jing Wu

The Affiliated Hospital of Southwest Medical University

Xin-Yi Du

The Affiliated Hospital of Southwest Medical University

Man Guo

The Affiliated Hospital of Southwest Medical University

Mei Wang

The Affiliated Hospital of Southwest Medical University

Xiao-Zhen Tan

The Affiliated Hospital of Southwest Medical University

Fang-Yuan Teng

The Affiliated Hospital of Southwest Medical University

Yong Xu (✉ xywyll@swmu.edu.cn)

Southwest Medical University

Research Article

Keywords: Osteoporosis, Fracture, Renin-angiotensin-aldosterone system (RASS), Angiotensin-converting enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB)

Posted Date: September 7th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-871694/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background

The angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) are prevalently used in the treatment of hypertension. Hypertension often presents with osteoporosis. However, over the past decade, it has been unclear whether long-term use of ACEI/ARB reduces fracture risk. This meta-analysis aims to investigate the potential clinical effects of ACEI/ARB on osteoporosis fracture (OF).

Methods

This meta-analysis was identified through PubMed, EMBASE, Cochrane Library, and Web of Science. Related studies about ACEI/ARB with the risk of fracture were published from inception to September, 2021.

Results

Nine qualified prospective designed studies, involving 3,649,785 subjects, were included in this analysis. Overall, the RR of ACEI compared with the non-users were 0.98 (95% CI: 0.88, 1.10; $P < 0.001$) for composite fractures and 0.96 (95% CI: 0.87, 1.05; $P = 0.048$) for hip fractures; the RR of ARB compared to the non-users were 0.82 (95% CI: 0.73, 0.91; $P < 0.001$) for composite fractures and 0.85 (95% CI: 0.74, 0.97; $P = 0.028$) for hip fractures. Furthermore, in the subgroup analysis, male may benefit from ARB (RR = 0.65, 95% CI 0.49, 0.89, $P = 0.028$), and the European may also benefit from ARB (RR = 0.86, 95% CI 0.80, 0.93, $P = 0.015$).

Conclusions

ACEI usage will not decrease the risk of osteoporosis fracture. On the contrary, ARB usage can decrease the risk of total fracture and hip fracture, especially for the male and European. Compared with ACEI, for patients at higher risk of fracture in cardiovascular diseases such as hypertension, the protective effect of ARB should be considered.

1. Background

With worldwide growth in aging populations, the number of people suffering from osteoporosis is also increasing and brings a battery of physical and mental pain and enormous economic burdens to the individual and society. Fracture, especially hip fracture, is a serious complication of osteoporosis. Hip fractures often resulting in paralysis and loss of self-care, and there was a twenty percent increase in mortality rate during the first year [1]. At present, known factors associated with the incidence of fractures include physical age [2], smoking [3], alcohol consumption [4] and physical exercise [5]. Besides, it is worth mentioning that the relationship between long-term drug use and fracture risks may require more attention.

The renin-angiotensin-aldosterone system (RAAS) is a pressure boosting regulatory system produced by the kidneys in the body that can produce angiotensin II (Ang II), thereby raising blood pressure. RAAS blockers have been widely used in patients with hypertension [6], and mainly contain the angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) in clinical practice. Strikingly, hypertension is also a common chronic disease, often presents with osteoporosis [7]. A prior study suggested that hypertension affects over 1 billion people worldwide [8]. Since hypertension often coexists with osteoporosis and the widely use of RAAS blockers for antihypertensive treatment, comprehending the effect of RAAS blockers on fracture has great clinical significance.

The relationship between RAAS blockers and bone health, structure, and metabolism has received increasing attention, but the answer remains uncertain as yet [9–11]. Abuhashish [9] showed that ACEI has a protective effect in estrogen-deficient osteoporotic rats. Meanwhile, Chen [10] reported that ARB can increase bone mass via suppressing RANKL-induced ERK1/2

phosphorylation. On the contrary, Yang [11] showed that captopril, one of the angiotensin-converting enzyme inhibitors, can poison the bone of normal mice. Before us, one meta-analysis has discussed the relationship between RASS blockers and fracture risk [12]. The previous meta-analysis has showed that both ACEI and ARB use was not associated with long-term risk of composite fractures, however, both ACEI and ARB were beneficial for hip fractures. But a careful search found that three recently published studies all produced different results from the previous paper [13–15]. To examine the effects of ACEI and ARB on fracture risk, an updated comprehensive meta-analysis, by far, was conducted.

2. Methods

2.1 Search strategy

The literature search for articles published from inception to September, 2021, was conducted in MEDLINE (via PubMed), EMBASE, Cochrane Library, and Web of Science. Mesh and free text terms used for the search were combined with methodological filters. All searches were limited to the English language and studies were conducted with healthy human 18 years old.

The following search terms were used: “Angiotensin-Converting Enzyme Inhibitors”, “Angiotensin II Receptor Blocker”, “Angiotensin Receptor Blockers”, “Inhibitors, ACE”, “ACEI”, “benazepril”, “captopril”, “enalapril”, “ARB”, “valsartan”, “irbesartan”, “losartan”; AND: “fracture”, “osteoporosis”, “fall injuries”, “bone mineral density”, “BMD”, “bone loss”. In order to find any missing studies, we also searched the reference lists of the full-text papers and reviewed studies in all relevant publications. Moreover, we also searched Google Scholar, World Cat Dissertations, conference abstracts of the American Society for Bone and Mineral Research, and the proceedings of the International Osteoporosis Foundation World Conference on Osteoporosis. The literature search process is based on the PRISMA form. Titles and abstracts were first to read and filtered by two independent reviewers, and relevant feasible articles were obtained in full. Any disagreements or uncertainties were discussed and resolved by the third investigator when needed.

2.2 Study eligibility criteria and selection

Three eligibility criteria were as follows: (1) study of human population aged 18 years or older that have exposure to ACEI/ARB therapy, (2) reporting fracture as an outcome, and (3) provided risk estimates, such as relative risks (RRs), odds ratios (ORs), hazard (HRs) ratios, or other measures that could be transformed into RRs, with 95% confidence intervals (CIs). Only cohort studies were considered. If different papers came from the same cohort, the paper with the most comprehensive design was brought into this analysis. Those citations both reviewers deemed irrelevant were excluded. Citations with disagreement were also included for a full review.

2.3 Study Quality

The quality of the final selected study was assessed using the Newcastle-Ottawa Scale (NOS), a nine-point scale to assess the quality of cohort study.

2.4 Data extraction

Two reviewers independently used data extraction tables to extract data from various included studies. The following items were evaluated and extracted: author and year of publication; methods (study design, mean follow-up years, geographic area); participants (sample size, age range, and gender); intervention type (ACEI, ARB); fracture site and the effect size. For subgroup analysis, we also stratified the data according to restriction factors, such as fracture site, sample size, location, gender, quality level, etc.

2.5 Statistical analysis

RRs were used as a common measure of the association between ACEI/ARB use and fracture risk [16]. In this meta-analysis, both ORs and HRs were transformed into RRs [17, 18]. For the best explanation of the heterogeneity between these studies, we used a random-effect model to calculate RRs and 95 % CIs [19]. Heterogeneity was assessed with both the Q statistic and the I^2

index [20]. Use forest plots to show the impact of each study on the overall results. Since most studies did not specify the dose or duration of ACEI/ARB use in their original reports, subgroup analysis by these variables was not performed. Sensitivity analyses were then performed for those studies with the best available evidence. A funnel plot was used to detect publication bias, Begg's test and Egger's tests were applied to measure funnel plot asymmetry. All the studies were conducted with Stata version 13, and statistical significance was set at a p-value of 0.05 or less.

3. Results

A total of 2916 potentially relevant citations were obtained through the all-sided search. As a result, we included 9 cohort studies [13–15, 21–26]. Appraisal of the original studies is shown in the **Supplementary Table 1**. The quality score ranged from 6 to 9. Our meta-analysis provides fracture data regarding 3,649,785 individuals. Details of the literature search and study selection flow based on the PRISMA statement are shown in Fig. 1. The general characteristics of the studies included in the meta-analysis are summarized in Table 1.

3.1 Study characteristics

The studies were from different regions: three from the America [13, 21, 26], three from Europe [14, 23, 24] and three from Asia [15, 22, 25]. The time of follow-up durations for the qualified studies ranged from 1 to 11 years, and the sample size ranged from 1144 to 1,586,554. Fractures were identified through medical records, imaging reports, questionnaires, or administrative data. The most frequent confounders, such as age, sex, and body mass index (BMI), were adjusted in these studies.

3.2 ACEI/ARB and the risk of composite fracture

The RR (95% CI) of ACEI/ARB usage associated with composite fractures is summarized in Fig. 2. Our meta-analysis showed that the usage of ACEI was not associated with a reduced risk of composite fractures (RR = 0.98, 95% CI 0.88, 1.10; $I^2 = 93.5\%$, $P < 0.001$). However, the risk of composite fractures was significantly reduced in subjects receiving ARB compared to non-users (RR = 0.82, 95% CI 0.74–0.92, $I^2 = 91.2\%$, $P < 0.001$).

3.3 ACEI/ARB and risk of hip fracture

The effects of ACEI/ARB on the risk of hip fracture are summarized in Fig. 3. When hip fracture was included as the only outcome measurement, however, the ACEI usage also cannot decelerate the risk of hip fracture (RR = 0.96, 95% CI 0.87–1.05, $I^2 = 62.1\%$, $P = 0.048$). In contrast, the usage of ARB would reduce the risk of hip fracture as compared with non-users (RR = 0.85, 95% CI 0.74, 0.97; $I^2 = 67.1\%$; $P = 0.028$).

3.4 Subgroup and Sensitivity Analysis

The relative risk of fracture associated with ACEI/ARB usage by subgroups are summarized in **Supplement Table 2** and **Supplement Table 3**. We conducted subgroup analysis in terms of fracture site, sample size, study location, gender and quality level. Interestingly, male may benefit from ARB blockers (RR = 0.65, 95% CI 0.49–0.89, $I^2 = 71.9\%$, $P = 0.028$). What's more, when grouped by regions, the European may benefit from ARB blockers (RR = 0.86, 95% CI 0.80–0.93, $I^2 = 76.1\%$, $P = 0.015$). However, in the female subgroup, the ACEI/ARB usage was not statistically significant. ACEI usage did not have a positive effect on fracture in any of the groups. In the grouping of sample size and quality level, both the combined results of five large-sample size cohort studies [13, 21–24] and five high-quality original studies (Quality Score ≥ 7) [13–15, 24, 26] have shown that ACEI cannot decelerate the risk of fracture, whereas, ARB use with a lower fracture risk. Unfortunately, most studies do not address drug doses or the effects of ACEI/ARB on other fracture sites (vertebral, wrist), which makes further analysis difficult. A sensitivity analysis about ACEI use showed that the exclusion of anyone study from the pooled analysis did not substantially vary the results (**Supplement Fig. 1**). The sensitivity analysis about ARB use showed that two studies [22, 24] were not covered (**Supplement Fig. 2**). When the two studies were excluded, the results did not change (RR = 0.78, 95% CI 0.74, 0.82; $I^2 = 87.5\%$, $P < 0.001$).

3.5 Publication bias

Publication bias is initially examined by drawing funnel plots. Then check it further with the Begg's test and Egger test. For ACEI use, the Begg's test for publication bias was not significant ($P = 0.754$), for ARB use ($P = 0.754$), for ACEI or ARB use ($P = 0.917$). The Egger test for ACEI use ($P = 0.823$), for ARB use ($P = 0.553$), for ACEI or ARB use ($P = 0.583$). Additionally, the use of the trim and fill correction procedure did not alter the results. No evidence of publication bias was detected.

4. Discussion

We conducted a comprehensive meta-analysis, including data from 9 qualified prospective cohort studies investigating the association between ACEI/ARB use and the risk of fracture. We found that ACEI use was not significantly associated with fracture risk, but ARB use was associated with a lower risk of fracture. Besides, by the subgroup analysis, male and the European may benefit from ARB.

Our updated meta-analysis differs in several important ways from the previous review performed by Kunutsor, S. K et al [12]. First, our meta-analysis involved more fracture events compared to the previous meta-analysis, as it combines the most recently published evidence on the topic to date. This study has more significant statistical power and adds three newly published studies with different results from previous ones. Furthermore, data from previous meta-analyses combined with hip fractures included only two studies. In contrast, we have added two new studies [13, 14] on hip fracture to make the results more reliable. This may have some influence on drug selection in clinical practice. In addition, we found that previous reports did not do a careful subgroup analysis, and in order to explore possible sources of heterogeneity in more detail than previously reported, subgroup analysis by sex and region showed that long-term use of ARB was associated with a greater reduction in fracture risk in men and in the European population.

The underlying mechanisms for the association between RAAS blockers use and the risk of fracture have been discussed for many years. Apart from the more well-known systemic RAAS activations, the tissue RAAS activation also plays an important role via the endocrine effects, which mediate important physiological stimuli including bone and osteoporosis [27]. A growing number of in vivo studies have shown that tissue RAAS may result in osteoporosis. This phenomenon might be via affecting the RANKL/RANK/OPG system to adjust bone metabolism [28–30]. Strikingly, tissue RAAS activity may also exert several other well-known osteoporosis risk factors or treatment modalities. Vitamin D inhibits renin gene transcription and suppresses RAAS activity [31]. Serum vitamin D level was negatively correlated with circulating RAAS activity [32, 33]. Besides, regular exercise could prevent tissue RAAS and inhibit future osteoporosis [34–36]. On the contrary, obesity may increase tissue RAAS activity [37].

Some mechanisms may explain the difference between ACEI and ARB. First, the activation of RAAS can increase the plasma concentration level of Ang II, which leads to a series of physiological effects. Although ACEI and ARB share the same mechanism pathway (renin-angiotensin-aldosterone system blocking), neither ACEI nor ARB can completely inhibit the production of Ang II and the toxic effects of Ang II [38]. The relative efficacy of ACEI in suppressing Ang II levels was less than that of ARB during chronic treatment [39]. Alternative enzymatic pathways bypassing ACEI may produce angiotensin II, which will be blocked by ARB [40]. Therefore, the ability of ACEI to maintain a consistent suppression of plasma and tissue Ang II levels is limited [41]. Second, the classical actions of Ang II are mediated by binding to the angiotensin II type 1 (AT1) receptors and angiotensin II type 2 (AT2) receptors [42]. AT1 receptors play a dominant role in the known actions of Ang II [43]. ARB can only reduce AT1 receptor activity, while ACEI can block multiple receptor activities including AT1 and AT2 receptors [44]. In some ways, however, the AT2 receptor can counteract several effects initiated by the AT1, though the mechanism remains unclear [45]. Third, compared with ARB, the mechanism of action of ACEI is more complex. ACEI is known to cause dry cough and angioedema [46] as it can inhibit bradykinin degradation [47]. Studies have shown that bradykinin, as a mediator of inflammation, can decrease osteoblasts differentiation and increase osteoclast formation [48]. Thus, ACEI may increase the risk of fracture by increasing bradykinin levels. In the future, the different effects of ACEI and ARB need to be further explored.

The subgroup analysis has shown that men would benefit from the ARB use, but it was not statistically significant for women. This may be because women's bone metabolism and bone density are more affected by estrogen than ARB [49], which has a smaller effect on fracture risk. Europeans would also benefit from the ARB use, which may be related to genes, diet and lifestyle in different regions, which needs more research. Our sensitivity analysis and subgroup analysis revealed that the differences in sample size and geographic region included in the original studies were major sources of heterogeneity. These results suggest that only long-term use of an ARB may be associated with a lower incidence of fracture, especially in men and European.

This study also has several limitations. First, due to the limited information we gathered from the original studies, we were unable to obtain treatment time and dose data for further analysis. Second, none of the included studies mentioned bone metabolism indexes and bone mineral density, so these aspects were not analyzed. Third, several drugs are often used concurrently in clinical, making it challenging to assess specific drug effects. So more high-quality studies are needed.

5. Conclusion

In conclusion, this meta-analysis demonstrated that ACEI cannot decelerate the risk of fracture, whereas, ARB has a protective effect on fracture risk. Hence, in clinical practice, ARB may be a priority when patients suffer from hypertension with a higher risk of fracture.

Abbreviations

RAAS: Renin-angiotensin-aldosterone system; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; OF: osteoporosis fractures; Ang II: angiotensin II; AT1: angiotensin II type 1; AT2: angiotensin II type 2

Declarations

Acknowledgments

We would like to express our thanks to the project of Sichuan Kidney Disease Clinical Medicine Research Center (NO.2019YFS0537-13), the key projects of Sichuan Science and Technology Department (NO.2019YFS0537, NO.2020YFS0456), the grants from Luzhou-Southwest Medical University cooperation project (NO.2018LZXNYD-PT01), and the Nation Natural Science Foundation of China (NO.81970676) for financial support.

Disclosure

The authors report no conflicts of interest in this work.

Data availability statement

The data used to support the findings of this study are included within the article and available from the corresponding author upon request.

Funding

The work was supported by the key projects of Sichuan Science and Technology Department (NO.2019YFS0537, NO.2020YFS0456), the grants from Luzhou-Southwest Medical University cooperation project (NO.2018LZXNYD-PT01), and the Nation Natural Science Foundation of China (NO.81970676).

Author contributions

All authors contributed to manuscript drafting, Study conception and design, review, and finalization. Data collection: JW, XYD, MG, MW. statistical analysis: JW, XYD, MG, FYT. Writing the manuscript draft: JW, MG, MW, FYT. Revising manuscript content: MW, XZT, FYT, YX. Assurance of data integrity: JW, MW, YX.

References

1. Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fractures. *BMJ*. 1993; 307: 1248-1250.
2. Drake MT, Murad MH, Mauck KF, Lane MA, Undavalli C, Elraiyah T, et al. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2012; 97: 1861-1870.
3. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, et al. Smoking and fracture risk: a meta-analysis. *Osteoporos Int*. 2005; 16: 155-162.
4. Yuan Z, Dawson N, Cooper GS, Einstadter D, Cebul R, Rimm AA. Effects of alcohol-related disease on hip fracture and mortality: a retrospective cohort study of hospitalized Medicare beneficiaries. *Am J Public Health*. 2001; 91: 1089-1093.
5. Qu X, Zhang X, Zhai Z, Li H, Liu X, Li H, et al. Association between physical activity and risk of fracture. *J Bone Miner Res*. 2014; 29: 202-211.
6. Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. *Circ Res*. 2015; 116: 960-975.
7. Ilic K, Obradovic N, Vujasinovic-Stupar N. The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review. *Calcif Tissue Int*. 2013; 92: 217-227.
8. Collaboration NCDRF. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. *Lancet*. 2017; 389: 37-55.
9. Abuhashish HM, Ahmed MM, Sabry D, Khattab MM, Al-Rejaie SS. ACE-2/Ang1-7/Mas cascade mediates ACE inhibitor, captopril, protective effects in estrogen-deficient osteoporotic rats. *Biomed Pharmacother*. 2017; 92: 58-68.
10. Chen S, Grover M, Sibai T, Black J, Rianon N, Rajagopal A, et al. Losartan increases bone mass and accelerates chondrocyte hypertrophy in developing skeleton. *Mol Genet Metab*. 2015; 115: 53-60.
11. Yang M, Xia C, Song Y, Zhao X, Wong MS, Zhang Y. Impairing effects of angiotensin-converting enzyme inhibitor Captopril on bone of normal mice. *Eur J Pharmacol*. 2016; 771: 40-47.
12. Kunutsor SK, Blom AW, Whitehouse MR, Kehoe PG, Laukkanen JA. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies. *Eur J Epidemiol*. 2017; 32: 947-959.
13. Carbone LD, Vasan S, Prentice RL, Harshfield G, Haring B, Cauley JA, et al. The renin-angiotensin aldosterone system and osteoporosis: findings from the Women's Health Initiative. *Osteoporos Int*. 2019; 30: 2039-2056.
14. Bokrantz T, Schioler L, Bostrom KB, Kahan T, Mellstrom D, Ljungman C, et al. Antihypertensive drug classes and the risk of hip fracture: results from the Swedish primary care cardiovascular database. *J Hypertens*. 2020; 38: 167-175.
15. Kao YT, Huang CY, Fang YA, Liu JC. The association between renin angiotensin aldosterone system blockers and future osteoporotic fractures in a hypertensive population - A population-based cohort study in Taiwan. *Int J Cardiol*. 2020; 305: 147-153.
16. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. *Am J Epidemiol*. 2003; 157: 940-943.
17. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. *JAMA*. 1998; 280: 1690-1691.

18. Danser AH, van den Meiracker AH. Response by Danser and van den Meiracker to Letter by Zhou and Zhou Regarding Article, "Hypertension: Renin-Angiotensin-Aldosterone System Alterations". *Circ Res.* 2016; 119: e105.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials.* 1986; 7: 177-188.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.* 2002; 21: 1539-1558.
21. Solomon DH, Mogun H, Garneau K, Fischer MA. Risk of fractures in older adults using antihypertensive medications. *J Bone Miner Res.* 2011; 26: 1561-1567.
22. Choi HJ, Park C, Lee YK, Ha YC, Jang S, Shin CS. Risk of fractures in subjects with antihypertensive medications: A nationwide claim study. *Int J Cardiol.* 2015; 184: 62-67.
23. Ruths S, Bakken MS, Ranhoff AH, Hunskaar S, Engesaeter LB, Engeland A. Risk of hip fracture among older people using antihypertensive drugs: a nationwide cohort study. *BMC Geriatr.* 2015; 15: 153.
24. Torstensson M, Hansen AH, Leth-Moller K, Jorgensen TS, Sahlberg M, Andersson C, et al. Danish register-based study on the association between specific cardiovascular drugs and fragility fractures. *BMJ Open.* 2015; 5: e009522.
25. Chen HY, Ma KY, Hsieh PL, Liou YS, Jong GP. Long-term Effects of Antihypertensive Drug Use and New-onset Osteoporotic Fracture in Elderly Patients: A Population-based Longitudinal Cohort Study. *Chin Med J (Engl).* 2016; 129: 2907-2912.
26. Kwok T, Leung J, Barrett-Connor E, Osteoporotic Fractures in Men Research G. ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men. *Age Ageing.* 2017; 46: 57-64.
27. Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, Takeshita S, et al. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. *J Bone Miner Res.* 2009; 24: 241-250.
28. Shuai B, Yang YP, Shen L, Zhu R, Xu XJ, Ma C, et al. Local renin-angiotensin system is associated with bone mineral density of glucocorticoid-induced osteoporosis patients. *Osteoporos Int.* 2015; 26: 1063-1071.
29. Hagiwara H, Hiruma Y, Inoue A, Yamaguchi A, Hirose S. Deceleration by angiotensin II of the differentiation and bone formation of rat calvarial osteoblastic cells. *J Endocrinol.* 1998; 156: 543-550.
30. Izu Y, Mizoguchi F, Kawamata A, Hayata T, Nakamoto T, Nakashima K, et al. Angiotensin II type 2 receptor blockade increases bone mass. *J Biol Chem.* 2009; 284: 4857-4864.
31. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest.* 2002; 110: 229-238.
32. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. *Clin Chim Acta.* 2010; 411: 1354-1360.
33. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. *Hypertension.* 2010; 55: 1283-1288.
34. Agarwal D, Welsch MA, Keller JN, Francis J. Chronic exercise modulates RAS components and improves balance between pro- and anti-inflammatory cytokines in the brain of SHR. *Basic Res Cardiol.* 2011; 106: 1069-1085.
35. Barretti DL, Magalhaes Fde C, Fernandes T, do Carmo EC, Rosa KT, Irigoyen MC, et al. Effects of aerobic exercise training on cardiac renin-angiotensin system in an obese Zucker rat strain. *PLoS One.* 2012; 7: e46114.

36. Ciampone S, Borges R, de Lima IP, Mesquita FF, Cambiucci EC, Gontijo JA. Long-term exercise attenuates blood pressure responsiveness and modulates kidney angiotensin II signalling and urinary sodium excretion in SHR. *J Renin Angiotensin Aldosterone Syst.* 2011; 12: 394-403.
37. Aubert J, Darimont C, Safonova I, Ailhaud G, Negrel R. Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells. *Biochem J.* 1997; 328 (Pt 2): 701-706.
38. Ferrario CM, VonCannon J, Jiao Y, Ahmad S, Bader M, Dell'Italia LJ, et al. Cardiac angiotensin-(1-12) expression and systemic hypertension in rats expressing the human angiotensinogen gene. *Am J Physiol Heart Circ Physiol.* 2016; 310: H995-1002.
39. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. *Eur Heart J.* 2000; 21: 53-57.
40. Park S, Bivona BJ, Kobori H, Seth DM, Chappell MC, Lazartigues E, et al. Major role for ACE-independent intrarenal ANG II formation in type II diabetes. *Am J Physiol Renal Physiol.* 2010; 298: F37-48.
41. Dusing R. Mega clinical trials which have shaped the RAS intervention clinical practice. *Ther Adv Cardiovasc Dis.* 2016; 10: 133-150.
42. El Muayed M, Stegbauer J, Oberhauser V, Vonend O, Rump LC. AT1 and AT2-receptor antagonists inhibit Ang II-mediated facilitation of noradrenaline release in human atria. *J Cardiovasc Pharmacol.* 2004; 43: 318-324.
43. Siragy HM. AT1 and AT2 receptor in the kidney: role in health and disease. *Semin Nephrol.* 2004; 24: 93-100.
44. Steckelings UM, Kaschina E, Unger T. The AT2 receptor—a matter of love and hate. *Peptides.* 2005; 26: 1401-1409.
45. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. *Pharmacol Rev.* 2000; 52: 415-472.
46. Israilli ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. *Ann Intern Med.* 1992; 117: 234-242.
47. Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE Inhibitor-Induced Angioedema: a Review. *Curr Hypertens Rep.* 2018; 20: 55.
48. Srivastava S, Sharma K, Kumar N, Roy P. Bradykinin regulates osteoblast differentiation by Akt/ERK/NFkappaB signaling axis. *J Cell Physiol.* 2014; 229: 2088-2105.
49. Khosla S. Update on estrogens and the skeleton. *J Clin Endocrinol Metab.* 2010; 95: 3569-3577.

Tables

Table 1 Characteristics of studies on the association of ACEI/ARB with the risk of fracture.

Study	Year	Country	Baseline age (year)	Men (%)	Follow-up (years)	Sample size	Fracture site	Effect size (CI 95%)	Adjustment main
Solomn ²¹	2011	USA	>=65	22.9	1	376061	all, hip, wrist, humerus and pelvic	all: ACEI:0.96 (0.90–1.04) ARB:0.76 (0.68–0.86) hip: ACEI:0.95 (0.84–1.07) ARB:0.77 (0.64–0.93)	Age, gender, race, Carlson comorbidity score, number of physician visits, acute-care hospitalizations, number of different medications, osteoporosis diagnoses and medications, prior fractures, BMD testing, use of medications with fracture associations.
Choi ²²	2015	South Korea	>=50	48.6	1.9	528522	all, vertebral, and non-vertebral	ACEI:1.68 (1.49–1.91) ARB:1.00 (0.95–1.05)	Age, gender, comorbidity score, diabetes, osteoporosis, osteoporosis treatment, and osteoporosis related diseases.
Ruths ²³	2015	Norway	72.8	44	5.2	906422	hip	ACEI:0.90 (0.90–1.00) ARB:0.80 (0.70–0.80)	NA
Torstensson ²⁴	2015	Denmark	>=65	81.2	6.7	1586554	all	ACEI:0.96 (0.95, 0.98) ARB:0.85 (0.83, 0.87)	Age, gender, calendar year, comorbidities and exposure to the other classes of CVD-drugs.
Chen ²⁵	2016	Taiwan	65-80	43.6	11	1144	all	ACEI:1.64 (1.01–2.66) ARB:0.89 (0.63–1.27)	Age, sex, comorbidities, and concurrent medication.

(continue Table 1)

Supplemental Table

Supplement Table1 Quality score used by the Newcastle–Ottawa scale (NOS)

Study	Year	Country	Baseline age (year)	Men (%)	Follow-up (years)	Sample size	Fracture site	Effect size (CI95%)	Adjustment main
kwok ²⁶	2016	USA	>=65	100	6.8	2573	non-vertebral, hip or wrist	ACEI:0.69 (0.52, 0.91) ARB:0.28 (0.14, 0.58)	Age, tricyclic antidepressants, thiazide use, previous fracture, inability to complete a narrow walk trial, falls in previous year, depressed mood, hip BMD, DM, cardiac failure, hypertension, duration of use of loop diuretic, statin and beta blocker.
Carbone ¹³	2019	USA	50-79	0	6.5	131793	all, hip, upper limb, lower limb, central body	all: ACEI:0.78(0.47, 1.29) ARB:1.16(0.69, 1.95) hip: ACEI:1.23(0.33, 4.59) ARB:0.52(0.06, 4.30)	Age, BMI, physical function, total calcium and vitamin-D, race/ethnicity, smoking status at baseline, parental history of hip fracture, history of fracture after age 55, reported health status, history of diabetes, CVD, hypertension, alcohol use at baseline, region, medication use at baseline.
Bokrantz ¹⁴	2020	Swedish	>=50	43.3	7	59246	hip	ACEI:1.05(0.95-1.15) ARB:0.98(0.87-1.11)	Age, sex, BMI, smoking and SBP level, concurrent medicate, drugs, ethnicity/origin, educational level and level of income.
kao ¹⁵	2020	Taiwan	>45	58.6	6	57470	all	ACEI:0.70(0.62-0.79) ARB:0.58(0.51-0.65)	NA

Study	Year	Selection	Comparability	Outcome	total score	quality level
Solomon	2011	4	1	1	6	Moderate
Choi	2015	3	1	2	6	Moderate
Ruths	2015	4	1	2	6	Moderate
Torstensson	2015	4	2	3	9	High
Chen	2016	4	1	1	6	Moderate
kwok	2016	4	1	2	7	High
Carbone	2019	4	2	2	8	High
Bokrantz	2020	4	2	2	8	High
kao	2020	4	1	2	7	High

Supplement Table 2 Subgroup analysis (ACEI)

Subgroup (ACEI)	No. of studies	Relative risk(95%CI)	Heterogeneity	
			I^2	P value
Fracture site				
hip	4	0.96(0.87, 1.05)	62.1%	0.048
non-vertebral	2	1.03(0.39, 2.76)	96.8%	<0.001
Sample size				
<100,000	4	0.91(0.67, 1.23)	91.6%	<0.001
>=100,000	5	1.05(0.92, 1.20)	95.3%	<0.001
Study Location				
Europe	3	0.96(0.90, 1.02)	77.8%	0.011
America	3	0.83(0.65, 1.07)	63.9%	0.063
Asia	3	1.23(0.61, 2.46)	98.0%	<0.001
Gender				
Male	3	0.91(0.75, 1.10)	77.3%	0.012
Female	3	1.00(0.95, 1.05)	0%	0.059
Quality Level				
Moderate	4	1.19(0.91, 1.55)	96.6%	<0.001
High	5	0.85(0.73, 1.00)	88.6%	<0.001

Supplement Table 3 Subgroup analysis (ARB)

Figures

Subgroup (ARB)	No. of studies	Relative risk(95%CI)	Heterogeneity	
			I^2	P value
Fracture site				
hip	4	0.85(0.74, 0.97)	67.1%	0.028
non-vertebral	2	0.47(0.09, 2.33)	92.2%	<0.001
Sample size				
<100,000		0.67(0.46, 1.00)	93.2%	<0.001
>=100,000		0.86(0.78, 0.95)	91.2%	<0.001
Study location				
Europe	3	0.86(0.80, 0.93)	76.1%	0.015
America	3	0.67(0.38, 1.19)	80.2%	0.006
Asia	3	0.80(0.52, 1.22)	97%	<0.001
Gender				
Male	3	0.65(0.49, 0.87)	71.9%	0.028
Female	2	1.07(0.94, 1.21)	0%	0.742
Quality Level				
Moderate	4	0.86(0.73, 1.01)	91.9%	<0.001
High	5	0.76(0.60, 0.96)	92.5%	<0.001




Figure 1

Search strategy and selection of studies.




Figure 2

ACEI/ARB and the risk of composite fracture.




Figure 3

ACEI/ARB and the risk of hip fracture.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementFig1.png](#)
- [SupplementFig2.png](#)